兴科蓉医药2026年中期财报：营收10.33亿元，经调整净利润19.90百万元

公告速递

Aug 28

2026年上半年信息

兴科蓉医药公告显示，截至2026年6月30日止六个月，营收为人民币1,032.5百万元，同比下降13.7%。按单位换算后，营收约10.33亿元。同期经调整净利润为19.90百万元，较去年同期减少约4.50百万元，降幅约18.4%。毛利率从2025年同期的10.9%升至12.0%，主要受采购成本下降及人民币兑美元升值影响。经营活动产生的现金流量从2025年同期的负13.30百万元转为本期净流入119.20百万元。

成本结构方面，销售及经销开支为37.40百万元，较上年同期增加约9.00百万元；行政开支录得41.60百万元，较去年同期上升约2.10百万元。

业务分项

进口药品销售在本期录得收入1,025.70百万元，同比减少160.60百万元，主要因为核心血液制品需求放缓。医美服务板块收入为6.80百万元，同比减少2.70百万元，受消费需求减弱拖累。

行业展望

公告提到，医药行业短期内仍将面对结构调整及政策环境变化，血液制品市场供应充足且竞争持续加剧。公司将继续优化市场布局，重点关注核心血液制品，提升渠道协同及经营效率，并在医美产品上持续创新和投入，以应对行业竞争与外部环境变化带来的挑战。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1174135193"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174135193\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174135193?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-28 16:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174135193","market":"us","top_or_hot":-1,"title":"兴科蓉医药2026年中期财报：营收10.33亿元，经调整净利润19.90百万元","media":"公告速递","content":"<p>2026年上半年信息</p>\n<p>兴科蓉医药公告显示，截至2026年6月30日止六个月，营收为人民币1,032.5百万元，同比下降13.7%。按单位换算后，营收约10.33亿元。同期经调整净利润为19.90百万元，较去年同期减少约4.50百万元，降幅约18.4%。毛利率从2025年同期的10.9%升至12.0%，主要受采购成本下降及人民币兑美元升值影响。经营活动产生的现金流量从2025年同期的负13.30百万元转为本期净流入119.20百万元。</p>\n<p>成本结构方面，销售及经销开支为37.40百万元，较上年同期增加约9.00百万元；行政开支录得41.60百万元，较去年同期上升约2.10百万元。</p>\n<p>业务分项</p>\n<p>进口药品销售在本期录得收入1,025.70百万元，同比减少160.60百万元，主要因为核心血液制品需求放缓。医美服务板块收入为6.80百万元，同比减少2.70百万元，受消费需求减弱拖累。</p>\n<p>行业展望</p>\n<p>公告提到，医药行业短期内仍将面对结构调整及政策环境变化，血液制品市场供应充足且竞争持续加剧。公司将继续优化市场布局，重点关注核心血液制品，提升渠道协同及经营效率，并在医美产品上持续创新和投入，以应对行业竞争与外部环境变化带来的挑战。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>兴科蓉医药2026年中期财报：营收10.33亿元，经调整净利润19.90百万元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n兴科蓉医药2026年中期财报：营收10.33亿元，经调整净利润19.90百万元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-08-28 16:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>2026年上半年信息</p>\n<p>兴科蓉医药公告显示，截至2026年6月30日止六个月，营收为人民币1,032.5百万元，同比下降13.7%。按单位换算后，营收约10.33亿元。同期经调整净利润为19.90百万元，较去年同期减少约4.50百万元，降幅约18.4%。毛利率从2025年同期的10.9%升至12.0%，主要受采购成本下降及人民币兑美元升值影响。经营活动产生的现金流量从2025年同期的负13.30百万元转为本期净流入119.20百万元。</p>\n<p>成本结构方面，销售及经销开支为37.40百万元，较上年同期增加约9.00百万元；行政开支录得41.60百万元，较去年同期上升约2.10百万元。</p>\n<p>业务分项</p>\n<p>进口药品销售在本期录得收入1,025.70百万元，同比减少160.60百万元，主要因为核心血液制品需求放缓。医美服务板块收入为6.80百万元，同比减少2.70百万元，受消费需求减弱拖累。</p>\n<p>行业展望</p>\n<p>公告提到，医药行业短期内仍将面对结构调整及政策环境变化，血液制品市场供应充足且竞争持续加剧。公司将继续优化市场布局，重点关注核心血液制品，提升渠道协同及经营效率，并在医美产品上持续创新和投入，以应对行业竞争与外部环境变化带来的挑战。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06833","symbol_name":"兴科蓉医药","start_time":0,"source_url":"","article_id":"1174135193","we_media_id":"1097772564","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174135193","pubTimestamp":1787907117,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"公告速递","introduction":"港美股公告全覆盖","home_visible":1,"id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"兴科蓉医药公告显示，截至2026年6月30日止六个月，营收为人民币1,032.5百万元，同比下降13.7%。按单位换算后，营收约10.33亿元。同期经调整净利润为19.90百万元，较去年同期减少约4.50百万元，降幅约18.4%。毛利率从2025年同期的10.9%升至12.0%，主要受采购成本下降及人民币兑美元升值影响。经营活动产生的现金流量从2025年同期的负13.30百万元转为本期净流入119.20百万元。进口药品销售在本期录得收入1,025.70百万元，同比减少160.60百万元，主要因为核心血液制品需求放缓。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06833":"兴科蓉医药"},"translate_title":"Xingke Rong Pharmaceutical's 2026 Interim Financial Report: Revenue of 1.033 billion yuan, adjusted net profit of 19.90 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06833":1},"content_text":"2026年上半年信息\n兴科蓉医药公告显示，截至2026年6月30日止六个月，营收为人民币1,032.5百万元，同比下降13.7%。按单位换算后，营收约10.33亿元。同期经调整净利润为19.90百万元，较去年同期减少约4.50百万元，降幅约18.4%。毛利率从2025年同期的10.9%升至12.0%，主要受采购成本下降及人民币兑美元升值影响。经营活动产生的现金流量从2025年同期的负13.30百万元转为本期净流入119.20百万元。\n成本结构方面，销售及经销开支为37.40百万元，较上年同期增加约9.00百万元；行政开支录得41.60百万元，较去年同期上升约2.10百万元。\n业务分项\n进口药品销售在本期录得收入1,025.70百万元，同比减少160.60百万元，主要因为核心血液制品需求放缓。医美服务板块收入为6.80百万元，同比减少2.70百万元，受消费需求减弱拖累。\n行业展望\n公告提到，医药行业短期内仍将面对结构调整及政策环境变化，血液制品市场供应充足且竞争持续加剧。公司将继续优化市场布局，重点关注核心血液制品，提升渠道协同及经营效率，并在医美产品上持续创新和投入，以应对行业竞争与外部环境变化带来的挑战。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}